INSANE: Moderna | Vintage Vibes

Personalized mRNA Melanoma Vaccine Cut Recurrence or Death Risk 42% in Phase 3 Trial, but Survival Data Pending

A personalized mRNA vaccine plus Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial. Overall survival data are not yet mature.

Medical Daily · Oct 24

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning

A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return

The Independent UK · Oct 22

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42%

Moderna CEO Stephane Bancel said the findings open a new chapter in cancer treatment

The Independent UK · Oct 22

Merck and Moderna Prepare FDA Filing for Personalized mRNA Melanoma Vaccine Paired with Keytruda After Phase 3 Results

Merck and Moderna are preparing to seek FDA approval for a personalized mRNA melanoma vaccine used with Keytruda. No filing date has been set.

Medical Daily · Oct 20

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

MarketBeat · Oct 19

Ebola vaccine trials 'reason for hope' in DR Congo and beyond

Five months into the Ebola outbreak in the Democratic Republic of Congo, there is still no approved vaccine against the rare Bundibugyo strain that has now caused more than 4,000 deaths. But candidates currently undergoing trials give reason to hope, according to Emanuele Capobianco of Gavi, the global vaccine alliance.

Radio France Internationale · Oct 18

Stocks Settle Higher on Earnings Optimism

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.59% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.51%. December E-mini S&P futures (ESZ26 ) rose +0.59%, and December E-mini...

Barchart · Oct 9

Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in playing MRNA shares at current levels.

Barchart · Oct 9

Earnings Optimism Lifts Stocks

The S&P 500 Index ($SPX ) (SPY ) is up by +0.42% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.40%. December E-mini S&P futures (ESZ26 ) are up +0.41%, and December E-mini...

Barchart · Oct 9

CSIRO to partner with pharmaceutical giant for research

A five-year partnership between CSIRO and Moderna has been unveiled to help develop research to biosecurity threats in Australia and the Pacific.

AAP · Oct 7